Daré Bioscience, Inc. (DARE)
DARE Stock Price Chart
Explore Daré Bioscience, Inc. interactive price chart. Choose custom timeframes to analyze DARE price movements and trends.
DARE Company Profile
Discover essential business fundamentals and corporate details for Daré Bioscience, Inc. (DARE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Apr 2014
Employees
21.00
Website
https://www.darebioscience.comCEO
Sabrina Martucci Johnson
Description
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
DARE Financial Timeline
Browse a chronological timeline of Daré Bioscience, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.33, while revenue estimate is $9.75K.
Earnings released on 14 Aug 2025
EPS came in at -$0.45 surpassing the estimated -$0.55 by +18.18%, while revenue for the quarter reached -$21.17K , missing expectations by -114.38%.
Earnings released on 13 May 2025
EPS came in at -$0.50 surpassing the estimated -$0.63 by +20.63%, while revenue for the quarter reached $25.43K , missing expectations by -95.76%.
Earnings released on 31 Mar 2025
EPS came in at -$0.64 surpassing the estimated -$0.66 by +3.03%, while revenue for the quarter reached -$63.65K , missing expectations by -106.36%.
Earnings released on 14 Nov 2024
EPS came in at -$0.55 surpassing the estimated -$0.60 by +8.33%, while revenue for the quarter reached $41.69K , missing expectations by -95.83%.
Earnings released on 12 Aug 2024
EPS came in at $1.52 surpassing the estimated -$0.57 by +366.67%, while revenue for the quarter reached $22.44K , missing expectations by -99.62%.
Stock split effective on 1 Jul 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2024
EPS came in at -$0.84 falling short of the estimated -$0.72 by -16.67%, while revenue for the quarter reached $9.30K , missing expectations by -96.42%.
Earnings released on 30 Dec 2023
EPS came in at -$0.69 , while revenue for the quarter reached $1.81M .
Earnings released on 9 Nov 2023
EPS came in at -$1.08 surpassing the estimated -$1.20 by +10.00%, while revenue for the quarter reached $1.00M , missing expectations by -20.63%.
Earnings released on 10 Aug 2023
EPS came in at -$1.20 matching the estimated -$1.20.
Earnings released on 11 May 2023
EPS came in at -$1.08 surpassing the estimated -$1.20 by +10.00%.
Earnings released on 30 Mar 2023
EPS came in at -$2.28 falling short of the estimated -$1.80 by -26.67%, while revenue for the quarter reached $10.00B , beating expectations by +502.41K%.
Earnings released on 10 Nov 2022
EPS came in at -$0.96 surpassing the estimated -$1.32 by +27.27%.
Earnings released on 9 Aug 2022
EPS came in at $0.06 surpassing the estimated -$0.06 by +196.98%, while revenue for the quarter reached $10.00M , meeting expectations.
Earnings released on 12 May 2022
EPS came in at -$1.20 surpassing the estimated -$1.68 by +28.57%.
Earnings released on 31 Mar 2022
EPS came in at -$2.16 surpassing the estimated -$2.52 by +14.29%.
Earnings released on 10 Nov 2021
EPS came in at -$2.16 falling short of the estimated -$1.32 by -63.64%.
Earnings released on 12 Aug 2021
EPS came in at -$2.16 falling short of the estimated -$1.80 by -20.00%.
Earnings released on 13 May 2021
EPS came in at -$1.92 surpassing the estimated -$2.76 by +30.43%.
Earnings released on 30 Mar 2021
EPS came in at -$2.64 falling short of the estimated -$2.40 by -10.00%.
Earnings released on 12 Nov 2020
EPS came in at -$2.88 falling short of the estimated -$1.80 by -60.00%.
DARE Stock Performance
Access detailed DARE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.